---
figid: PMC9315482__pharmaceutics-14-01344-g006
figtitle: Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion
  in Cancer Immunotherapy
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9315482
filename: pharmaceutics-14-01344-g006.jpg
figlink: /pmc/articles/PMC9315482/figure/pharmaceutics-14-01344-f006/
number: F6
caption: Diagrammatic illustration of immune checkpoint blockade therapies. Inhibiting
  the ligand–receptor interaction of PD-1/PD-L1 to prevent the activation of PD-1/PD-L1
  signaling pathway, leading to T cell activation and reduction of tumor cell proliferation.
papertitle: Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion
  in Cancer Immunotherapy.
reftext: Kaili Deng, et al. Pharmaceutics. 2022 Jul;14(7):1344.
year: '2022'
doi: 10.3390/pharmaceutics14071344
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords: small interfering RNA | immune evasion | nanoparticles | tumor microenvironment
  | immunotherapy
automl_pathway: 0.9062673
figid_alias: PMC9315482__F6
figtype: Figure
redirect_from: /figures/PMC9315482__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9315482__pharmaceutics-14-01344-g006.html
  '@type': Dataset
  description: Diagrammatic illustration of immune checkpoint blockade therapies.
    Inhibiting the ligand–receptor interaction of PD-1/PD-L1 to prevent the activation
    of PD-1/PD-L1 signaling pathway, leading to T cell activation and reduction of
    tumor cell proliferation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - RPL29P31
---
